News
Halozyme Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Halozyme Therapeutics, Inc.? Here are five stocks we like better.
- Record Q2 performance: Revenue rose 48% year over year to $481 million, while royalty revenue increased
BioMarin Pharmaceutical Q2 Earnings Call Highlights
Key Points
- Interested in BioMarin Pharmaceutical Inc.? Here are five stocks we like better.
- BioMarin’s second-quarter revenue nearly reached $1 billion, rising 20% year over year. The company
Orion Energy Targets $95M-$97M Revenue After Margin Gains at Annual Meeting
Key Points
- Interested in Orion Energy Systems, Inc.? Here are five stocks we like better.
- Fiscal 2026 results improved: Revenue rose to $86.3 million from $79.7 million, gross margin increased
Zillow Group Q2 Earnings Call Highlights
Zillow Group (NASDAQ:Z) reported second-quarter revenue growth that exceeded its outlook, led by gains in its For Sale and
EQS-News: RHÖN-KLINIKUM AG mit weiterhin stabiler Entwicklung im Halbjahr 2026
EQS-News: RHÖN-KLINIKUM AG mit weiterhin stabiler Entwicklung im Halbjahr 2026
EQS-News: Evotec und Odyssey Therapeutics starten KI-gestützte F&E-Kooperation in Autoimmun- und Entzündungserkrankungen
EQS-News: Evotec und Odyssey Therapeutics starten KI-gestützte F&E-Kooperation in Autoimmun- und Entzündungserkrankungen
Revolution Medicines Q2 Earnings Call Highlights
Key Points
- Interested in Revolution Medicines, Inc.? Here are five stocks we like better.
- Daraxonrasib moved closer to commercialization: The FDA accepted Revolution Medicines’ application for
LifeMD Q2 Earnings Call Highlights
Key Points
- Interested in LifeMD, Inc.? Here are five stocks we like better.
- Q2 profitability missed expectations: LifeMD reported $47.3 million in revenue and an adjusted EBITDA loss of about
Exelixis Q2 Earnings Call Highlights
Key Points
- Interested in Exelixis, Inc.? Here are five stocks we like better.
- Q2 revenue reached approximately $629 million, driven by $573 million in U.S. cabozantinib franchise net product
Cirrus Logic Q1 Earnings Call Highlights
Key Points
- Interested in Cirrus Logic, Inc.? Here are five stocks we like better.
- Record quarterly performance: Cirrus Logic reported fiscal Q1 revenue of $460 million, up 13% year over year
Clover Health Investments Q2 Earnings Call Highlights
Key Points
- Interested in Clover Health Investments, Corp.? Here are five stocks we like better.
- Clover Health reported strong second-quarter results: Medicare Advantage membership rose 48%
Carlsmed Q2 Earnings Call Highlights
Key Points
- Interested in Carlsmed, Inc.? Here are five stocks we like better.
- Carlsmed’s Q2 revenue rose 57% year over year to $18.9 million, driven by higher adoption of its aprevo lumbar
Insulet Q2 Earnings Call Highlights
Key Points
- Interested in Insulet Corporation? Here are five stocks we like better.
- Strong Q2 performance: Insulet reported revenue of $802 million, up 22.7% on a constant-currency basis, while
BeOne Medicines Q2 Earnings Call Highlights
Key Points
- Interested in BeOne Medicines Ltd. - Sponsored ADR? Here are five stocks we like better.
- Strong second-quarter performance: BeOne Medicines reported revenue of $1.7 billion, up 30%
Orion Energy Systems Q1 Earnings Call Highlights
Key Points
- Interested in Orion Energy Systems, Inc.? Here are five stocks we like better.
- Strong first-quarter performance: Revenue increased 32% year over year to $25.7 million, while net
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
Key Points
- Interested in NewAmsterdam Pharma Company N.V.? Here are five stocks we like better.
- PREVAIL is the key near-term catalyst: NewAmsterdam expects to reach its interim event target by
LivaNova Q2 Earnings Call Highlights
Key Points
- Interested in LivaNova PLC? Here are five stocks we like better.
- Record Q2 performance: Revenue rose 9.8% year over year on a constant-currency basis to $391 million, while adjusted
DaVita Q2 Earnings Call Highlights
Key Points
- Interested in DaVita Inc.? Here are five stocks we like better.
- DaVita reaffirmed its 2026 outlook after reporting second-quarter adjusted operating income of $579 million, adjusted
Travere Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Travere Therapeutics, Inc.? Here are five stocks we like better.
- Record FILSPARI performance: Travere reported $169.6 million in total second-quarter revenue
Ultragenyx Pharmaceutical Q2 Earnings Call Highlights
Key Points
- Interested in Ultragenyx Pharmaceutical Inc.? Here are five stocks we like better.
- Ultragenyx reported record Q2 revenue of $214 million, led by Crysvita’s $156 million contribution
Match Group Q2 Earnings Call Highlights
Key Points
- Interested in Match Group Inc.? Here are five stocks we like better.
- Match Group reported mixed Q2 results: Revenue fell 1% year over year to $853 million, while adjusted EBITDA
Gilead Sciences Q2 Earnings Call Highlights
Key Points
- Interested in Gilead Sciences, Inc.? Here are five stocks we like better.
- Base business sales rose 10% year over year to $7.6 billion, led by HIV, oncology and liver treatments
ACADIA Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in ACADIA Pharmaceuticals Inc.? Here are five stocks we like better.
- Second-quarter revenue rose 17% year over year to $308 million, driven by DAYBUE sales of $125 million
BellRing Brands Q3 Earnings Call Highlights
Key Points
- Interested in BellRing Brands Inc.? Here are five stocks we like better.
- Third-quarter sales rose 4%, led by better-than-expected performance from Premier Protein and a 27% increase
Armada Hoffler Properties Q2 Earnings Call Highlights
Key Points
- Interested in Armada Hoffler Properties, Inc.? Here are five stocks we like better.
- Armada Hoffler raised its 2026 FFO guidance to $0.53–$0.57 per diluted share after reporting